Cardiovascular Risk of Atorvastatin on Hyperlipidemia with Chronic Kidney Disease
Wang Shufang
Huang Shutian
Abstract：Objective To explore the impact of atorvastatin on renal function and cardiovascular disease in hyperlipidemic patients with chronic kidney disease (CKD).Methods A total of 243 patients with CKD and hyperlipidemia was randomly divided into atorv-astatin treatment group (n=120),and the control group(n=123).All patients were follow up for 2 years.The general information, blood pressure,and lipids were collected.Results In the baseline,the LDL C and HDL C were different in moderate CKD and nor-mal renal function/mild CKD.During follow up,the change in eGFR in patients with moderate CKD was not significantly(P>0.05) in those assigned to receive atorvastatin.Compared with moderate CKD,incidence of cardiovascular disease was low in normal renal function/mild CKD insufficiency (P<0.05).In the moderate CKD group pravastatin significantly could reduced CVD (P<0.05). Conclusion Risk of CVD was higher in patients with moderate CKD compared with those with normal renal function/mild CKD,and it was significantly reduced by treatment with atorvastatin.Atorvastatin also exerted slight effects on renal function in patients with moderate CKD.
Keywords：chronic kidney diseasecardiovascular diseaseatorvastatinhyperlipidemia
Publication Date：2014-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 802-804 )